Trending Up0.0400 (0.9238%)
  • Bid / Lots
    4.1900/ 2
  • Ask / Lots
    4.3700/ 2
  • Open / Previous Close
    4.3400 / 4.3300
  • Day Range
    Low 4.2450
    High 4.3700
  • 52 Week Range
    Low 3.5000
    High 9.2499
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 4.33
09:32 ET8094.34
09:35 ET64744.34
09:44 ET11514.25
09:48 ET1504.25
10:04 ET34254.3
10:15 ET1004.32
10:26 ET35144.32
10:31 ET7894.32
10:51 ET4104.32
10:54 ET24174.34
10:58 ET2004.33
11:00 ET9004.34
11:36 ET1724.3065
11:41 ET2004.305
11:50 ET1004.32
11:54 ET9004.31
11:57 ET2504.31
12:01 ET23714.29
12:06 ET2504.3
12:08 ET5004.29
12:10 ET22554.26
12:15 ET1004.26
12:26 ET17574.265
12:35 ET32104.245
12:39 ET1004.2599
12:48 ET5004.26
12:51 ET2004.28
01:15 ET2704.28
01:38 ET10004.2882
01:40 ET25814.295
01:42 ET14104.305
01:44 ET2004.29
01:49 ET6784.294
02:25 ET7024.2601
02:48 ET5004.27
02:54 ET1004.27
02:57 ET1004.27
02:59 ET1004.28
03:06 ET2004.275
03:14 ET1004.28
03:15 ET2474.28
03:17 ET1704.29
03:19 ET5004.2889
03:21 ET2504.285
03:24 ET4014.3
03:33 ET5814.31
03:37 ET1004.3
03:39 ET1054.28
03:42 ET1004.28
03:44 ET2584.275
03:48 ET7084.29
03:51 ET46204.32
03:53 ET17244.32
03:55 ET77594.37
03:57 ET21934.36
04:00 ET289454.37
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
United StatesATOS
Atossa Therapeutics Inc
United StatesCTXR
Citius Pharmaceuticals Inc
United StatesALLK
Allakos Inc
United StatesBCAB
Bioatla Inc
United StatesKNTE
Kinnate Biopharma Inc
As of 2024-02-25

Company Information

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Contact Information

10080 N Wolfe Road, Suite Sw3-200CUPERTINO, CA, United States 95014


Independent Chairman of the Board
Parag Saxena
President, Chief Executive Officer, Director
Laxminarayan Bhat
Chief Financial Officer
Narayan Prabhu
Independent Director
Leslie Funtleyder
Independent Director
Richard Margolin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.